Labiotech.eu

News and Trends 15 Aug 2016

These 3 Synbio Startups did a ‘perfect pitch’ at IndieBio’s Demo Day

On July 28th 2016, IndieBio EU, the world’s first biotech accelerator, held their demo day in the lovely surroundings of Cork City Gaol. On the night, 13 startups pitched their ideas and products in the hopes of securing investment to take their ideas to the next level. Firebreathers and a live band added the finishing touch to […]

August 15, 2016 - 4 minutesmins - By Denise Neves Gameiro

astrazeneca moderna mrna biotech investing

News and Trends 12 Aug 2016

mRNA Money-magnet increases its Pile of Cash to over €1.3Bn

Moderna is taking Biotech investing to new heights, as it has now increased total fundraising&partnership cash to an unbelievable €1.34Bn ($1.5Bn). It can thank AstraZeneca, which is now adding €126M more to its investment. Amid dropping revenues and pipeline cuts, AstraZeneca remains steadily focused on innovation and Biotech. After all, this was the strategy CEO Pascal […]

August 12, 2016 - 2 minutesmins - By Denise Neves Gameiro

entrechem oviedo secondary metabolite engineering

News and Trends 12 Aug 2016

EntreChem is going Back to the Future of Drug Discovery

We leave the Netherlands with a smile after visiting FF Pharma in Utrecht this week. Once again, we depart to another part of Europe and this time we’re heading to the North of Spain. Oviedo, the main capital of the Spanish Asturias region, is our final destination and is also where EntreChem, our Biotech of the […]

August 12, 2016 - 2 minutesmins - By Joachim Eeckhout

hereditary edema KVD818 kalvista protease inhibitor

News and Trends 11 Aug 2016

New First-in-Human trial for rare Hereditary Angioedema begins in the UK

A new drug by KalVista is starting a Phase I trial. The drug could become a preventive treatment for people suffering for hereditary angioedema, a rare genetic condition that can be life-threatening. Based in the Tetricus Science Park (UK), KalVista targets proteases that are involved in diseases. It develops small molecule inhibitors for plasma kallikrein, an enzyme involved […]

August 11, 2016 - 2 minutesmins - By Denise Neves Gameiro

astrazeneca phase III failure nsclc selumetinib

News and Trends 11 Aug 2016

This new Phase III Failure adds up to AstraZeneca’s Troubles

AstraZeneca’s oncology pipeline takes a hit, as one of its Phase III trials failed to meet its primary endpoint. The program targeted advanced non-small lung cancer. It looks like it’s up to immunotherapies now. Now struggling for a while, AstraZeneca has been refocusing on cancer and investing big in new candidates. The strategy hasn’t yet […]

August 11, 2016 - 3 minutesmins - By Denise Neves Gameiro

amazon synthetic dna helixworks indiebio

News and Trends 10 Aug 2016

Why on Earth would someone order DNA on Amazon?

Yes, you can now add a customized genetic sequence to your shopping cart, thanks to a Biotech startup. But what would you need it for? Let’s say, you are buying some really cool Biotech reading material online. You can now head to the ‘Industrial & Scientific’ section of Amazon and get a GeneSlice with that. For […]

August 10, 2016 - 4 minutesmins - By Denise Neves Gameiro

rheumatoid arthritis anti il 6r ablynx abbvie

News and Trends 9 Aug 2016

Ablynx’ Best-In-Class Antibody might not be that ‘Compelling’ to Abbvie

Ablynx has disclosed ‘compelling’ results for its Phase IIb trial in rheumatoid arthritis. But it might have a hard time compelling AbbVie to pay €68M to continue the candidate’s development, as the grass is not as green as it seems… Ablynx‘s impressive list of big Pharma collaborations could soon need an update, as its $840 partnership with […]

August 9, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 9 Aug 2016

Yes, Biotech can help you win the Olympic Games of Rio

The world’s eyes are set on the 2016 edition of the Summer Olympics, which started in Rio de Janeiro last week. I had a look at how Biotech has been involved in the Olympics – and how it could define it in the future. The Summer Olympics of 2016 have been marked by its fair […]

August 9, 2016 - 5 minutesmins - By Denise Neves Gameiro

sleep homeostasis sandman channel oxford cncb

News and Trends 8 Aug 2016

The Brain’s Sleep Switch was just discovered, zZz …

Researchers from the University of Oxford have discovered how certain neurons control when we go to sleep. The biology behind it involves an ion channel that reacts to the ‘happy chemical’ dopamine, changing places in the neurons. Sleep is essential to health, with the Center for Disease Control even calling insufficient sleep a public health […]

August 8, 2016 - 3 minutesmins - By Denise Neves Gameiro

endometriosis treatment womens health biotech

News and Trends 8 Aug 2016

A €580M Collaboration for Endometriosis Therapies breaks into Clinical Development

Update (24/07/2017): Bayer and Evotec have announced a second compound from their partnership made it to clinical trials in humans. Consequently, they have decided to extend the partnership for an extra year and develop 4 candidates instead of the original 3. Originally published on 08/08/2016 An endometriosis therapy is now moving to clinical development. It’s […]

August 8, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 5 Aug 2016

Dutch FF Pharma has a Promising Immunotherapy to fight Crohn’s Disease

Arrivederci Italia! We’re going to fly up to the Netherlands for another Biotech-related adventure! This time, we’re visiting Utrecht, the fourth most populated city in the country and home-base to FF Pharma, our Biotech of the Week! City: Utrecht (The Netherlands) Founded: 2012 Employees: N/A Financial Data: €4M Total Raised (as of 12/2015) CEO: Mark De Boer Mission: FF […]

August 5, 2016 - 2 minutesmins - By Joachim Eeckhout

News and Trends 4 Aug 2016

Roche drops Partnership for Hepatitis Immunotherapy

While everybody wants to get the next immunotherapy on the market, Roche is turning its back on one. It’s leaving the partnership with Inovio, which focuses on developing a DNA-based immunotherapy to treat Hepatitis B. Previously, Roche has left projects to focus on immunotherapies, particularly in the hype field of immuno-oncology. This was an important […]

August 4, 2016 - 3 minutesmins - By Denise Neves Gameiro

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us